Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-01

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to understand the effect of the dietary supplement "Nicotinamide mononucleotide" on metabolic health in people.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of NMN Supplementation on Organ System Biology

NCT04571008

Glucose Metabolism Disorders

COMPLETED NA

Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults

NCT04862338

Healthy Volunteers

COMPLETED NA

The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.

NCT06907329

Immunosenescence Metabolism

RECRUITING NA

Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity

NCT04664361

Physical Activity Muscle Recovery

COMPLETED NA

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

NCT02812238

Atherosclerosis Diabetes Coronary Artery Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease. Accordingly, the investigators will evaluate the effect of NMN on how well the hormone insulin works to control blood sugar. The investigators will also look at the effects of NMN on blood lipids; body fat and liver fat; and other blood, fat tissue and muscle tissue markers of cardiovascular (heart) and metabolic health. Data from studies conducted in rodents have shown that NMN supplementation has beneficial effects on cardiovascular and metabolic health, but this has not yet been studied in people.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glucose Metabolism Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Intervention will last at least 8 weeks in the form of two capsules.

NMN supplementation

Group Type EXPERIMENTAL

NMN supplement

Intervention Type DIETARY_SUPPLEMENT

Intervention will last at least 8 weeks in the form of two capsules (250 mg total).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NMN supplement

Intervention will last at least 8 weeks in the form of two capsules (250 mg total).

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention will last at least 8 weeks in the form of two capsules.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

nicotinamide mononucleotide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women 55-75 years old
* BMI 25.0-44.9 kg/m²
* Fasting plasma glucose concentration ≥100 mg/dl, OGTT 2 hour glucose ≥ 140 mg/dl, HbA1C ≥5.7%, or HOMA-IR ≥2.5

Exclusion Criteria

* Diabetes
* Premenopausal or menopause \<1 year
* Persons who have received hormone replacement therapy within the past 6 months
* Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period.
* Structured exercise: ≥75 min/wk of vigorous exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥150 min/wk of low intensity physical activity (e.g., brisk walking).
* Unstable weight (\>3% change during the last 2 months before entering the study)
* Significant organ system dysfunction or disease
* Present cancer or history of cancer that has been in remission for \<5 years
* Polycystic ovary syndrome
* Major psychiatric illness
* Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study
* Metal implants
* Smokes cigarettes
* Persons who consume \>14 units of alcohol per week
* Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.

Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes